Niko-Lek Mint (Nicotine)

Niko-Lek Mint, a nicotine replacement therapy, is used to manage nicotine withdrawal in the context of smoking cessation.

• Smoking cessation: helps adult smokers quit by reducing cravings and withdrawal symptoms.
• Nicotine dependence: provides controlled nicotine to ease the transition away from cigarettes.
• Tobacco use disorder: supports gradual reduction of tobacco intake while maintaining nicotine levels.

• Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central nervous system, stimulating the release of dopamine and other neurotransmitters. This mimics the pharmacologic effects of smoked tobacco, thereby reducing withdrawal symptoms and cravings associated with smoking cessation.

Niko-Lek Mint may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Mouth irritation or soreness
• Nausea or upset stomach
• Dizziness or light‑headedness
• Headache
• Increased salivation or hiccups
• Throat discomfort

Serious or Rare Side Effects

• Elevated blood pressure or hypertension
• Irregular heart rhythm (arrhythmia)
• Chest pain or palpitations
• Severe allergic reaction (rash, swelling, difficulty breathing)
• Persistent vomiting
• Signs of nicotine toxicity (confusion, seizures).

Before using Niko-Lek Mint, consider the following safety measures.

• Cardiovascular assessment: patients with recent heart attack or uncontrolled hypertension should use with caution.
• Pregnancy and lactation: consult a healthcare professional before use, as safety data are limited.
• Age restriction: intended for adult smokers; not recommended for individuals under 18 years.
• Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously to prevent excess exposure.
• Storage: Store at ambient temperature: keep in the original pack, protect from moisture and direct heat.

Nicotine may interact with other medicines, altering their effects or increasing adverse reactions.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may amplify hypertensive response.
• Beta‑blockers: nicotine‑induced tachycardia may be masked, complicating cardiovascular monitoring.

Moderate Interactions (Monitor Closely)

• CYP2A6 inhibitors (e.g., methoxsalen): can reduce nicotine metabolism, increasing plasma levels.
• Anticoagulants (e.g., warfarin): nicotine may affect platelet function, requiring INR monitoring.
• Alcohol: concurrent use can enhance nicotine dependence and cardiovascular strain.